CONTENTS
NEW RESEARCH
Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial
Subodh Verma, Lawrence A Leiter, Bernard Zinman, Abhinav Sharma, Michaela Mattheus, David Fitchett, Jyothis George, Anne Pernille Ofstad, Mikhail N Kosiborod, Christoph Wanner,
Silvio E Inzucchi – 4-10
Inrange: comparison of the second-generation basal insulin analogues glargine 300 u/ml and degludec 100 u/ml in persons with type 1 diabetes using continuous glucose monitoring— study design
Tadej Battelino, Zsolt Bosnyak, Thomas Danne, Bhaswati Mukherjee, Steve Edelman, Valerie Pilorget, Pratik Choudhary, Eric Renard, Richard Bergenstal – 11-21
Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials
Tobias Täger, Dan Atar, Stefan Agewall, Hugo A Katus, Morten Grundtvig, John G F Cleland, Andrew L Clark, Hanna Fröhlich, Lutz Frankenstein -22-39
Switching from neutral protamine hagedorn insulin to insulin glargine 300 u/ml improves glycaemic control and reduces hypoglycaemia risk: results of a multicentre, prospective, observational study
Wolnik, D. Wiza, T. Szczepanik, A. Syta, T. Klupa -40-50
Glucometers in diabetes patients’ self-control and the principles of selecting them in pharmacies in Ukraine
I O Vlasenko, L L Davtyan -51-66
Long-term results of treatment of patients with type 2 diabetes with sodium-glucose cotransporter-2 (sglt2) inhibitors
Kravchun N.O., Zemlyanitsyna O.V., Dunaeva I.P., Dorosh O.G. -67-74
Mechanisms of genetic predisposition to autoimmune lesions of the thyroid gland
Nagibin V.S., Sayenko Ya.A. -75-83
Microbiota and endocrine-metabolic diseases
Borovets M. O., Urbanovych A. M. – 84-91